Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk
Background: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Hence, the aim of this research was to explore galectin-3 and FGF-23 in rel...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Medical Biochemists of Serbia, Belgrade
2025-01-01
|
| Series: | Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501085K.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096632379801600 |
|---|---|
| author | Klisic Aleksandra Gluscevic Sanja Karakasis Paschalis Kotur-Stevuljevic Jelena Ninic Ana |
| author_facet | Klisic Aleksandra Gluscevic Sanja Karakasis Paschalis Kotur-Stevuljevic Jelena Ninic Ana |
| author_sort | Klisic Aleksandra |
| collection | DOAJ |
| description | Background: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Hence, the aim of this research was to explore galectin-3 and FGF-23 in relation to T2D, as well as to examine the potential association of these biomarkers with atherosclerotic cardiovascular disease (ASCVD) risk score in Montenegrin adults. Methods: A total of 35 T2D patients and 36 controls were consecutively enrolled. Serum galectin-3 and FGF-23 were determined by ELISA. The ASCVD risk score was calculated. Results: Higher serum galectin-3 levels were shown in T2D patients (p=0.016) in comparison with the control group. The increase in galectin-3 levels for 1 ng/mL showed an 8.5% higher probability of T2D occurrence (OR=1.085, p=0.015). FGF-23 levels did not differ between the control and the T2D group. Serum galectin-3 correlated with FGF23 (r=0.390, p=0.001). Both galectin-3 (r=0.306, p=0.010) and FGF-23 (r=0.332, p=0.005) correlated with ASCVD risk score in bivariate Spearman's correlation analysis, but these correlations were not retained in binary logistic regression analysis. Conclusions: Serum galectin-3 levels but not FGF-23 are higher in T2D patients. Serum galectin-3 correlated with FGF-23. Although both biomarkers were correlated with the ASCVD risk score, further statistical analysis did not confirm their independent associations with cardiovascular risk. Studies with a large sample size are needed to further explore this issue. |
| format | Article |
| id | doaj-art-f3633c2c26d24f0ea3aa7030144f9148 |
| institution | Kabale University |
| issn | 1452-8258 1452-8266 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Society of Medical Biochemists of Serbia, Belgrade |
| record_format | Article |
| series | Journal of Medical Biochemistry |
| spelling | doaj-art-f3633c2c26d24f0ea3aa7030144f91482025-02-05T13:11:23ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662025-01-01441859210.5937/jomb0-504711452-82582501085KSerum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular riskKlisic Aleksandra0https://orcid.org/0000-0001-7870-0996Gluscevic Sanja1Karakasis Paschalis2Kotur-Stevuljevic Jelena3https://orcid.org/0000-0002-6980-3069Ninic Ana4https://orcid.org/0000-0003-3838-1606University of Montenegro-Faculty of Medicine, Podgorica, MontenegroClinical Center of Montenegro, Department of Neurology, Podgorica, MontenegroAristotle University of Thessaloniki, General Hospital "Hippokration", Second Department of Cardiology, Thessaloniki, GreeceUniversity of Belgrade, Faculty of Pharmacy, Department for Medical Biochemistry, Belgrade, SerbiaUniversity of Belgrade, Faculty of Pharmacy, Department for Medical Biochemistry, Belgrade, SerbiaBackground: The clinical utility of galectin-3 and fibroblast growth factor 23 (FGF-23) needs to be further explored since previous studies show divergent results in relation to type 2 diabetes (T2D) and cardiovascular risk. Hence, the aim of this research was to explore galectin-3 and FGF-23 in relation to T2D, as well as to examine the potential association of these biomarkers with atherosclerotic cardiovascular disease (ASCVD) risk score in Montenegrin adults. Methods: A total of 35 T2D patients and 36 controls were consecutively enrolled. Serum galectin-3 and FGF-23 were determined by ELISA. The ASCVD risk score was calculated. Results: Higher serum galectin-3 levels were shown in T2D patients (p=0.016) in comparison with the control group. The increase in galectin-3 levels for 1 ng/mL showed an 8.5% higher probability of T2D occurrence (OR=1.085, p=0.015). FGF-23 levels did not differ between the control and the T2D group. Serum galectin-3 correlated with FGF23 (r=0.390, p=0.001). Both galectin-3 (r=0.306, p=0.010) and FGF-23 (r=0.332, p=0.005) correlated with ASCVD risk score in bivariate Spearman's correlation analysis, but these correlations were not retained in binary logistic regression analysis. Conclusions: Serum galectin-3 levels but not FGF-23 are higher in T2D patients. Serum galectin-3 correlated with FGF-23. Although both biomarkers were correlated with the ASCVD risk score, further statistical analysis did not confirm their independent associations with cardiovascular risk. Studies with a large sample size are needed to further explore this issue.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501085K.pdfdiabetesinflammationinsulin resistancebiomarkers |
| spellingShingle | Klisic Aleksandra Gluscevic Sanja Karakasis Paschalis Kotur-Stevuljevic Jelena Ninic Ana Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk Journal of Medical Biochemistry diabetes inflammation insulin resistance biomarkers |
| title | Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk |
| title_full | Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk |
| title_fullStr | Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk |
| title_full_unstemmed | Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk |
| title_short | Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk |
| title_sort | serum galectin 3 and fibroblast growth factor 23 levels in relation with type 2 diabetes and cardiovascular risk |
| topic | diabetes inflammation insulin resistance biomarkers |
| url | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501085K.pdf |
| work_keys_str_mv | AT klisicaleksandra serumgalectin3andfibroblastgrowthfactor23levelsinrelationwithtype2diabetesandcardiovascularrisk AT gluscevicsanja serumgalectin3andfibroblastgrowthfactor23levelsinrelationwithtype2diabetesandcardiovascularrisk AT karakasispaschalis serumgalectin3andfibroblastgrowthfactor23levelsinrelationwithtype2diabetesandcardiovascularrisk AT koturstevuljevicjelena serumgalectin3andfibroblastgrowthfactor23levelsinrelationwithtype2diabetesandcardiovascularrisk AT ninicana serumgalectin3andfibroblastgrowthfactor23levelsinrelationwithtype2diabetesandcardiovascularrisk |